J
Junji Tsurutani
Researcher at Showa University
Publications - 199
Citations - 11370
Junji Tsurutani is an academic researcher from Showa University. The author has contributed to research in topics: Cancer & Metastatic breast cancer. The author has an hindex of 36, co-authored 169 publications receiving 8629 citations. Previous affiliations of Junji Tsurutani include Nagasaki University & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi,Satoshi Morita,Yasushi Yatabe,Shunichi Negoro,Isamu Okamoto,Junji Tsurutani,Takashi Seto,Miyako Satouchi,Hirohito Tada,Tomonori Hirashima,Kazuhiro Asami,Nobuyuki Katakami,Minoru Takada,Hiroshige Yoshioka,Kazuhiko Shibata,Shinzoh Kudoh,Eiji Shimizu,Hiroshi Saito,Shinichi Toyooka,Kazuhiko Nakagawa,Masahiro Fukuoka +20 more
TL;DR: In this article, an open label, phase 3 study (WJTOG3405) with recruitment between March 31, 2006, and June 22, 2009, at 36 centers in Japan was conducted.
Journal ArticleDOI
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi,Cristina Saura,Toshinari Yamashita,Yeonhee Park,Sung Bae Kim,Kenji Tamura,Fabrice Andre,Hiroji Iwata,Yoshinori Ito,Junji Tsurutani,Junji Tsurutani,Joohyuk Sohn,Neelima Denduluri,Christophe Perrin,Kenjiro Aogi,Eriko Tokunaga,Seock-Ah Im,Keun Seok Lee,Sara A. Hurvitz,Javier Cortes,Caleb Lee,Shuquan Chen,Lin Zhang,Javad Shahidi,Antoine Yver,Ian E. Krop +25 more
TL;DR: Tastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer and requires attention to pulmonary symptoms and careful monitoring.
Journal ArticleDOI
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Shanu Modi,William Jacot,Toshinari Yamashita,Joohyuk Sohn,Maria Vidal,Eriko Tokunaga,Junji Tsurutani,Naoto Ueno,Aleix Prat,Yee Soo Chae,Keun Seok Lee,Naoki Niikura,Yeon Hee Park,Bing Xue,Xiao-juan Wang,Miguel Gil-Gil,Wei Liu,Jean-Yves Pierga,Seock-Ah Im,Halle C. F. Moore,Hope S. Rugo,Rinat Yerushalmi,Flora Zagouri,Andrea Gombos,Sung-Bae Kim,Qiang Liu,Ting Luo,Cristina Saura,Peter Schmid,Tao Sun,Dhiraj Gambhire,Lotus Yung,Yibin Wang,Jasmeet Singh,Patrik Vitazka,Gerold Meinhardt,Nadia Harbeck,David Cameron +37 more
TL;DR: In this phase 3 trial involving patients with HER2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the physician's choice of chemotherapy.
Journal ArticleDOI
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors.
Roberto Bianco,Incheol Shin,Christoph A. Ritter,F. Michael Yakes,Andrea D. Basso,Neal Rosen,Junji Tsurutani,Phillip A. Dennis,Gordon B. Mills,Carlos L. Arteaga +9 more
TL;DR: Combined blockade of the EGFR tyrosine kinase and Akt should be considered as a therapeutic approach in EGFR-expressing tumor cells with concomitant amplification(s) of PI3K-Akt signaling.
Journal ArticleDOI
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
Shanu Modi,Haeseong Park,Rashmi Krishna Murthy,Hiroji Iwata,Kenji Tamura,Junji Tsurutani,Alvaro Moreno-Aspitia,Toshihiko Doi,Yasuaki Sagara,Charles H. Redfern,Ian E. Krop,Caleb Lee,Yoshihiko Fujisaki,Masahiro Sugihara,Lin Zhang,Javad Shahidi,Shunji Takahashi +16 more
TL;DR: The novel Her2-targeted ADC, T-DXd, demonstrated promising preliminary antitumor activity in patients with HER2-low breast cancer and should be monitored closely and proactively managed.